What is Deciphex?
Deciphex operates at the intersection of medical technology and artificial intelligence, providing a sophisticated platform designed to network and accelerate the workflows of pathologists globally. The company's core value proposition lies in its ability to enhance diagnostic efficiency, thereby mitigating the operational pressures currently facing clinical laboratories. By integrating digital pathology with proprietary AI algorithms, Deciphex is positioning itself as a critical infrastructure provider for modern healthcare systems, enabling faster, more accurate, and scalable diagnostic outcomes in an increasingly data-driven medical landscape.
How much funding has Deciphex raised?
Deciphex has raised a total of $67.1M across 6 funding rounds:
Other Financing Round
$2.3M
Series A
$6.2M
Series B
$11.5M
Other Financing Round
$4.2M
Debt
$10.6M
Series C
$32.3M
Other Financing Round (2019): $2.3M, investors not publicly disclosed
Series A (2020): $6.2M led by Halo Business Angel Network, Act Venture Capital Ltd, NextSteps Capital LLC, Enterprise Ireland, GI Partners of Illinois LLC, and Irrus Investments
Series B (2022): $11.5M supported by Act Venture Capital and Charles River Laboratories India Private
Other Financing Round (2023): $4.2M featuring Seroba Life Sciences Management
Debt (2023): $10.6M backed by Claret Capital Partners
Series C (2025): $32.3M with participation from Charles River, NextSteps Capital, Irrus Investments, Molten Ventures, Seroba, ACT Venture Capital, and hban.cn
Key Investors in Deciphex
Molten Ventures
A prominent European venture capital firm that provides patient capital and extensive international networks to support high-growth, disruptive technology companies.
Seroba
A specialized European life sciences venture capital firm focused on backing innovative biotech and medtech companies that address significant unmet medical needs.
Charles River
A global leader in providing essential products and services to accelerate drug discovery, development, and manufacturing for the pharmaceutical and biotechnology industries.
What's next for Deciphex?
With the successful closure of this Series C financing, Deciphex is well-positioned to scale its international operations and further refine its AI-driven diagnostic suite. The strategic infusion of capital will likely be directed toward expanding its footprint in key global markets and accelerating product development cycles to meet the evolving needs of clinical and research institutions. As the company transitions into this next phase of growth, the focus will remain on solidifying its market leadership, fostering strategic partnerships with global life sciences entities, and continuing to deliver high-impact solutions that address the most pressing challenges in contemporary pathology.
See full Deciphex company page
